People can react in different ways to some medicines depending on the amount of certain antibodies they have in their blood. It is important when developing new medicines to understand how these antibodies may affect the medicine.
In this study we will investigate the properties of these antibodies and how they may affect a medicine which is being developed by GSK.
Participation: 40 volunteers from Cambridge BioResource took part in this this study.
Organisation: This study was organised by Dr Andrew Bayliffe from GlaxoSmithKline.
